文献速递消化道肿瘤与早癌炎症性肠病

链状双歧杆菌通过激活CD8+ T细胞增强微卫星稳定结直肠癌的抗PD-1疗效

Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells.
PubMed 文献 · Gut · 2026-04-09

本研究在110例结直肠癌患者和112例健康对照的粪便中发现链状双歧杆菌显著减少,并在3个已发表宏基因组数据集(198例结直肠癌患者和176例正常受试者)中验证。口服链状双歧杆菌在多种结直肠癌模型中抑制肿瘤生长,并通过其代谢物乙酸盐增强微卫星稳定结直肠癌模型中抗PD-1疗法的疗效,机制涉及乙酸盐直接结合CD8+ T细胞MCT-4并激活MAPK信号。

要点

  • 链状双歧杆菌在结直肠癌患者粪便中显著减少,并在多个独立数据集中验证。
  • 口服链状双歧杆菌在多种结直肠癌模型中抑制肿瘤生长。
  • 链状双歧杆菌来源的乙酸盐通过激活CD8+ T细胞增强微卫星稳定结直肠癌的抗PD-1疗效。

核心结论

  • 链状双歧杆菌通过产生乙酸盐抑制结直肠肿瘤发生,并通过激活CD8+ T细胞提高微卫星稳定结直肠癌的抗PD-1疗效,是潜在的免疫治疗佐剂。

研究设计与样本

  • 在内部队列中评估结直肠癌患者细菌丰度,并在已发表数据集中验证。
  • 在MC38(微卫星不稳定高)和CT26(微卫星稳定)同基因小鼠模型、Apc min/+转基因小鼠及AOM/DSS诱导的结直肠癌模型中确定候选细菌与抗PD-1疗法的效果。
  • 通过多色流式细胞术和免疫组化染色识别免疫景观变化。
  • 对粪便、血清和肿瘤组织进行代谢组学分析。

主要发现

  • 链状双歧杆菌在110例结直肠癌患者粪便中较112例健康对照显著减少,并在3个已发表宏基因组数据集(198例结直肠癌患者和176例正常受试者)中验证。
  • 口服链状双歧杆菌在MC38和CT26同基因模型、Apcmin/+小鼠及AOM/DSS诱导的结直肠癌模型中抑制肿瘤生长。
  • 在Apcmin/+小鼠和CT26同种异体移植的微卫星稳定结直肠癌模型中,链状双歧杆菌通过增强瘤内CD8+ T细胞浸润与抗PD-1疗法协同。
  • 链状双歧杆菌来源的乙酸盐被鉴定为功能代谢物,直接结合CD8+ T细胞中的MCT-4并激活丝裂原活化蛋白激酶信号。
  • 药理学和遗传学MCT4消融在体外消除了乙酸盐介导的CD8+ T细胞激活。

临床怎么用

  • 链状双歧杆菌可作为改善结直肠癌免疫治疗(尤其是微卫星稳定型)的潜在佐剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Certain gut bacteria are associated with improved responses to immunotherapy. OBJECTIVE: We aim to identify bacteria that inhibit colorectal cancer (CRC) progression and enhance immunotherapy efficacy. DESIGN: The abundance of bacteria in CRC patients was evaluated in our in-house cohorts and validated in published datasets. The effect of candidate bacterium with anti-PD-1 therapy was determined in two syngeneic mouse models of MC38 (microsatellite instability-high) and CT26 (microsatellite stable, MSS), transgenic Apc min/+ mice and azoxymethane/dextran sulfate sodium (AOM/DSS)-induced CRC tumourigenesis model. Immune landscape changes were identified by multicolour flow cytometry and immunohistochemistry staining. Metabolomic profiling was performed on stool, serum and tumour tissues. RESULTS: Bifidobacterium catenulatum was significantly depleted in stool samples of 110 CRC patients compared with 112 healthy controls, which was further validated in 3 published metagenomic datasets comprising 198 CRC patients and 176 normal subjects. Oral administration of B. catenulatum inhibited tumour growths in multiple CRC models including MC38 and CT26 syngeneic models, Apcmin/+ mice and AOM/DSS-induced CRC. Notably, B. catenulatum synergised with anti-PD-1 therapy through enhancing intratumoural CD8+ T cell infiltration in MSS CRC models of Apcmin/+ mice and CT26 allografts. B. catenulatum-derived acetate was identified as the functional metabolite. Mechanistically, acetate directly bound to MCT-4 in CD8+ T cells and activated mitogen-activated protein kinase signalling. Pharmacological and genetic MCT4 ablation abolished acetate-mediated CD8+ T cell activation in vitro. CONCLUSION: B. catenulatum suppresses colorectal tumourigenesis through generating acetate, which also improves anti-PD-1 efficacy through activating CD8+ T cells in MSS CRC. B. catenulatum is a potential adjuvant to improve immunotherapy against CRC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Li X, Xie M, Kang JX, et al. Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells. Gut. 2026. PMID: 41956809. doi:10.1136/gutjnl-2025-336025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。